1. A QALY is [still] a QALY is [still] a QALY?
- Author
-
Hamideh Mahdiani, Nikolai Münch, and Norbert W. Paul
- Subjects
Cost-effectiveness ,Biomedical Ethics ,Equity ,cancer ,Medical philosophy. Medical ethics ,R723-726 - Abstract
Abstract Despite clinical evidence of drug superiority, therapeutic modalities, like combination immunotherapy, are mostly considered cost-ineffective due to their high costs per life year(s) gained. This paper, taking an ethical stand, reevaluates the standard cost-effectiveness analysis with that of the more recent justice-enhanced methods and concludes by pointing out the shortcomings of the current methodologies.
- Published
- 2024
- Full Text
- View/download PDF